Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Supplemental material
  • Version history
  • Article usage
  • Citations to this article
Advertisement

Resource and Technical AdvanceIn-Press PreviewGeneticsOncology Open Access | 10.1172/jci.insight.211025

TSC2-Mutant Yucatan Minipig Cardiac Rhabdomyoma Model Reveals mTORC1 Activation and MITF/TFE Expression Signature

Elias Bou Farhat,1 Heng Du,1 Chrystalle Katte Carreon,2 Jad Halawi,1 Sophie Kudler,1 Magdalena Losko,1 Zachary T. Herbert,3 Adrienne L. Watson,4 Daniel Carlson,5 Dennis A. Webster,5 Derek M. Korpela,5 David M. Meredith,6 Elizabeth P. Henske,1 and David J. Kwiatkowski1

1Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital, Boston, United States of America

2The Stella and Richard Van Praagh Cardiac Registry, Departments of Cardiolo, Boston Children’s Hospital, Boston, United States of America

3Molecular Biology Core Facilities, Dana-Farber Cancer Institute, Boston, United States of America

4Recombinetics Inc., Eagan, United States of America

5TOG Technologies, LLC. d/b/a Recombinetics, New Brighton, United States of America

6Department of Pathology, Brigham and Women’s Hospital, Boston, United States of America

Find articles by Bou Farhat, E. in: PubMed | Google Scholar

1Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital, Boston, United States of America

2The Stella and Richard Van Praagh Cardiac Registry, Departments of Cardiolo, Boston Children’s Hospital, Boston, United States of America

3Molecular Biology Core Facilities, Dana-Farber Cancer Institute, Boston, United States of America

4Recombinetics Inc., Eagan, United States of America

5TOG Technologies, LLC. d/b/a Recombinetics, New Brighton, United States of America

6Department of Pathology, Brigham and Women’s Hospital, Boston, United States of America

Find articles by Du, H. in: PubMed | Google Scholar |

1Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital, Boston, United States of America

2The Stella and Richard Van Praagh Cardiac Registry, Departments of Cardiolo, Boston Children’s Hospital, Boston, United States of America

3Molecular Biology Core Facilities, Dana-Farber Cancer Institute, Boston, United States of America

4Recombinetics Inc., Eagan, United States of America

5TOG Technologies, LLC. d/b/a Recombinetics, New Brighton, United States of America

6Department of Pathology, Brigham and Women’s Hospital, Boston, United States of America

Find articles by Carreon, C. in: PubMed | Google Scholar

1Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital, Boston, United States of America

2The Stella and Richard Van Praagh Cardiac Registry, Departments of Cardiolo, Boston Children’s Hospital, Boston, United States of America

3Molecular Biology Core Facilities, Dana-Farber Cancer Institute, Boston, United States of America

4Recombinetics Inc., Eagan, United States of America

5TOG Technologies, LLC. d/b/a Recombinetics, New Brighton, United States of America

6Department of Pathology, Brigham and Women’s Hospital, Boston, United States of America

Find articles by Halawi, J. in: PubMed | Google Scholar

1Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital, Boston, United States of America

2The Stella and Richard Van Praagh Cardiac Registry, Departments of Cardiolo, Boston Children’s Hospital, Boston, United States of America

3Molecular Biology Core Facilities, Dana-Farber Cancer Institute, Boston, United States of America

4Recombinetics Inc., Eagan, United States of America

5TOG Technologies, LLC. d/b/a Recombinetics, New Brighton, United States of America

6Department of Pathology, Brigham and Women’s Hospital, Boston, United States of America

Find articles by Kudler, S. in: PubMed | Google Scholar

1Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital, Boston, United States of America

2The Stella and Richard Van Praagh Cardiac Registry, Departments of Cardiolo, Boston Children’s Hospital, Boston, United States of America

3Molecular Biology Core Facilities, Dana-Farber Cancer Institute, Boston, United States of America

4Recombinetics Inc., Eagan, United States of America

5TOG Technologies, LLC. d/b/a Recombinetics, New Brighton, United States of America

6Department of Pathology, Brigham and Women’s Hospital, Boston, United States of America

Find articles by Losko, M. in: PubMed | Google Scholar

1Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital, Boston, United States of America

2The Stella and Richard Van Praagh Cardiac Registry, Departments of Cardiolo, Boston Children’s Hospital, Boston, United States of America

3Molecular Biology Core Facilities, Dana-Farber Cancer Institute, Boston, United States of America

4Recombinetics Inc., Eagan, United States of America

5TOG Technologies, LLC. d/b/a Recombinetics, New Brighton, United States of America

6Department of Pathology, Brigham and Women’s Hospital, Boston, United States of America

Find articles by Herbert, Z. in: PubMed | Google Scholar |

1Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital, Boston, United States of America

2The Stella and Richard Van Praagh Cardiac Registry, Departments of Cardiolo, Boston Children’s Hospital, Boston, United States of America

3Molecular Biology Core Facilities, Dana-Farber Cancer Institute, Boston, United States of America

4Recombinetics Inc., Eagan, United States of America

5TOG Technologies, LLC. d/b/a Recombinetics, New Brighton, United States of America

6Department of Pathology, Brigham and Women’s Hospital, Boston, United States of America

Find articles by Watson, A. in: PubMed | Google Scholar

1Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital, Boston, United States of America

2The Stella and Richard Van Praagh Cardiac Registry, Departments of Cardiolo, Boston Children’s Hospital, Boston, United States of America

3Molecular Biology Core Facilities, Dana-Farber Cancer Institute, Boston, United States of America

4Recombinetics Inc., Eagan, United States of America

5TOG Technologies, LLC. d/b/a Recombinetics, New Brighton, United States of America

6Department of Pathology, Brigham and Women’s Hospital, Boston, United States of America

Find articles by Carlson, D. in: PubMed | Google Scholar

1Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital, Boston, United States of America

2The Stella and Richard Van Praagh Cardiac Registry, Departments of Cardiolo, Boston Children’s Hospital, Boston, United States of America

3Molecular Biology Core Facilities, Dana-Farber Cancer Institute, Boston, United States of America

4Recombinetics Inc., Eagan, United States of America

5TOG Technologies, LLC. d/b/a Recombinetics, New Brighton, United States of America

6Department of Pathology, Brigham and Women’s Hospital, Boston, United States of America

Find articles by Webster, D. in: PubMed | Google Scholar

1Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital, Boston, United States of America

2The Stella and Richard Van Praagh Cardiac Registry, Departments of Cardiolo, Boston Children’s Hospital, Boston, United States of America

3Molecular Biology Core Facilities, Dana-Farber Cancer Institute, Boston, United States of America

4Recombinetics Inc., Eagan, United States of America

5TOG Technologies, LLC. d/b/a Recombinetics, New Brighton, United States of America

6Department of Pathology, Brigham and Women’s Hospital, Boston, United States of America

Find articles by Korpela, D. in: PubMed | Google Scholar

1Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital, Boston, United States of America

2The Stella and Richard Van Praagh Cardiac Registry, Departments of Cardiolo, Boston Children’s Hospital, Boston, United States of America

3Molecular Biology Core Facilities, Dana-Farber Cancer Institute, Boston, United States of America

4Recombinetics Inc., Eagan, United States of America

5TOG Technologies, LLC. d/b/a Recombinetics, New Brighton, United States of America

6Department of Pathology, Brigham and Women’s Hospital, Boston, United States of America

Find articles by Meredith, D. in: PubMed | Google Scholar

1Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital, Boston, United States of America

2The Stella and Richard Van Praagh Cardiac Registry, Departments of Cardiolo, Boston Children’s Hospital, Boston, United States of America

3Molecular Biology Core Facilities, Dana-Farber Cancer Institute, Boston, United States of America

4Recombinetics Inc., Eagan, United States of America

5TOG Technologies, LLC. d/b/a Recombinetics, New Brighton, United States of America

6Department of Pathology, Brigham and Women’s Hospital, Boston, United States of America

Find articles by Henske, E. in: PubMed | Google Scholar |

1Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital, Boston, United States of America

2The Stella and Richard Van Praagh Cardiac Registry, Departments of Cardiolo, Boston Children’s Hospital, Boston, United States of America

3Molecular Biology Core Facilities, Dana-Farber Cancer Institute, Boston, United States of America

4Recombinetics Inc., Eagan, United States of America

5TOG Technologies, LLC. d/b/a Recombinetics, New Brighton, United States of America

6Department of Pathology, Brigham and Women’s Hospital, Boston, United States of America

Find articles by Kwiatkowski, D. in: PubMed | Google Scholar |

Published November 5, 2026 - More info

JCI Insight. https://doi.org/10.1172/jci.insight.211025.
Copyright © 2026, Bou Farhat et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published November 5, 2026 - Version history
View PDF
Abstract

Tuberous sclerosis complex (TSC) is an inherited tumor predisposition syndrome caused by pathogenic variants in TSC1 or TSC2, yet no animal model faithfully recapitulates the cardiac rhabdomyomas (CR) that are among its earliest manifestations. We generated a heterozygous TSC2-mutant Yucatan minipig carrying the recurrent pathogenic TSC2 p.Arg505* variant and characterized its cardiac phenotype using histopathology, immunohistochemistry, and RNA sequencing. TSC2-mutant minipigs consistently developed multiple CR that closely resembled human lesions, including enlarged glycogen-rich spider cells and activation of mechanistic target of rapamycin complex 1 (mTORC1) signaling. Comparative transcriptomic analyses demonstrated enrichment of a conserved TSC-associated gene expression program and activation of microphthalmia/transcription factor E (MITF/TFE)-regulated lysosomal pathways in both human and minipig tumors. Although other manifestations of TSC were not observed during the first year of life, this large-animal model faithfully reproduced the principal histopathologic and molecular features of human CR. These findings have established the TSC2-mutant Yucatan minipig as what we believe to be the first large-animal model of TSC-associated CR and provide a physiologically relevant platform for investigating tumor pathogenesis, mechanisms of spontaneous regression, and therapeutic strategies targeting mTORC1- and MITF/TFE-dependent signaling.

Supplemental material

View

View supplemental tables

Version history
  • Version 1 (November 5, 2026): In-Press Preview

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Supplemental material
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts